News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Feb 19, 2021

Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women
Feb 18, 2021

Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

- Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 -
Feb 12, 2021

Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

- Durable Tumor Responses Experienced Among Patients Previously Treated with Immunotherapy in Second Cohort of EV-201 Trial -
Feb 12, 2021

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

- Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy -
Feb 4, 2021

Astellas expands Top Management, names Percival Barretto-Ko as Chief Business Officer; Yoshitsugu Shitaka as Chief Scientific Officer

Oncology head Mark Reisenauer named Astellas US President; Masahide Goto named President at Astellas Institute for Regenerative Medicine
Feb 3, 2021

Astellas' XOSPATA® (gilteritinib) Receives Conditional Approval by China's National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

- Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings
Jan 28, 2021

Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
Jan 6, 2021

FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
Dec 21, 2020

Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Dec 14, 2020

Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise

Show per page